1. A method for parenteral administration of a composition, comprising parenteral administration to a patient of a composition comprising krill oil in an oil-in-water emulsion. The method according to claim 1, wherein the krill oil is present in an amount effective to increase the physical stability of the emulsion, compared with the specified physical stability of an identical emulsion containing egg lecithin instead of krill oil. The method according to claim 1, wherein the krill oil is present in an amount effective to increase the chemical stability of the emulsion, compared with the chemical stability of an identical emulsion containing alpha tocopherol instead of krill oil. The method of claim 1, wherein the composition comprises a highly lipophilic drug and krill oil is present in an amount effective to solubilize said lipophilic drug. The method of claim 1, wherein the composition comprises n3 fatty acids in an amount effective to reduce the deleterious effects of the drug on vital organs, including inflammation, oxidative stress, immunomodulation and / or ischemic events. The method of claim 1, wherein said method is a method of treating endotoxemia in cases of severe sepsis. The method of claim 1, wherein said method is a method of treating a patient with toxic blood levels of highly lipophilic drugs. The method of claim 1, wherein said composition is substantially free of egg lecithin. The method of claim 1, wherein the krill oil contains EPA and DHA. The method according to claim 1, where the specified composition essentially does not contain n3-FAs obtained from fish sources. The method according to claim 1, where1. Способ парентерального введения композиции, включающий парентеральное введение пациенту композиции, включающей крилевое масло в эмульсии типа масло-в-воде.2. Способ по п.1, где крилевое масло присутствует в количестве, эффективном для повышения физической стабильности эмульсии, по сравнению с указанной физической стабильностью идентичной эму
